160 related articles for article (PubMed ID: 9399614)
1. Experience with crystalline niacin as the preferred drug for dyslipidemia in a specialty clinic.
Rindone JP; Arriola OG
Pharmacotherapy; 1997; 17(6):1296-9. PubMed ID: 9399614
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and safety of immediate-release niacin in patients with ischemic cardiopathy. Experience of the Instituto Nacional de Cardiología "Ignacio Chávez"].
Morato Hernández ML; Ichazo Cerro MS; Alvarado Vega AG; Zamora González J; Cardoso Saldaña GC; Posadas Romero C
Arch Inst Cardiol Mex; 2000; 70(4):367-76. PubMed ID: 11075282
[TBL] [Abstract][Full Text] [Related]
3. Niacin-based therapy for dyslipidemia: past evidence and future advances.
Ito MK
Am J Manag Care; 2002 Sep; 8(12 Suppl):S315-22. PubMed ID: 12240703
[TBL] [Abstract][Full Text] [Related]
4. Adipokines and treatment with niacin.
Westphal S; Borucki K; Taneva E; Makarova R; Luley C
Metabolism; 2006 Oct; 55(10):1283-5. PubMed ID: 16979396
[TBL] [Abstract][Full Text] [Related]
5. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
Duvall WL; Blazing MA; Saxena S; Guyton JR
J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
[TBL] [Abstract][Full Text] [Related]
6. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
8. Management of dyslipidemia in the high-risk patient.
Stein EA
Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
[TBL] [Abstract][Full Text] [Related]
9. Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options.
Jones PH
Am Heart J; 2004 Jul; 148(1 Suppl):S9-13. PubMed ID: 15211327
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).
Ballantyne CM; Davidson MH; McKenney J; Keller LH; Bajorunas DR; Karas RH
Am J Cardiol; 2008 May; 101(10):1428-36. PubMed ID: 18471454
[TBL] [Abstract][Full Text] [Related]
11. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
[TBL] [Abstract][Full Text] [Related]
12. Niacin for lipid disorders. Indications, effectiveness, and safety.
Brown WV
Postgrad Med; 1995 Aug; 98(2):185-9, 192-3. PubMed ID: 7630846
[TBL] [Abstract][Full Text] [Related]
13. Treating hyperlipidemia, Part III: Drug therapy.
Smith DA; Karmally W; Brown WV
Geriatrics; 1987 Aug; 42(8):55-9, 62. PubMed ID: 3110017
[TBL] [Abstract][Full Text] [Related]
14. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
15. New perspectives on the use of niacin in the treatment of lipid disorders.
McKenney J
Arch Intern Med; 2004 Apr; 164(7):697-705. PubMed ID: 15078639
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of dyslipoproteinemia risk factor. Lipid therapy must become multidimensional].
MMW Fortschr Med; 2008 Jun; 150(26-27):52-3. PubMed ID: 18681233
[No Abstract] [Full Text] [Related]
17. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
[TBL] [Abstract][Full Text] [Related]
18. Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease.
Nordøy A
Minerva Med; 2002 Oct; 93(5):357-63. PubMed ID: 12410168
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic treatment of type 2 diabetic dyslipidemia.
Moon YS; Kashyap ML
Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
[TBL] [Abstract][Full Text] [Related]
20. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
Manfredi R; Chiodo F
J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
